ACCELERATE and the 11 members of the ALADDIN consortium have launched a new educational program on strategic and regulatory science in paediatric oncology drug development to foster expertise and strengthen true multi-stakeholder collaboration.
The ALADDIN project offers a comprehensive program for current and future generations of experts to come through a transversal and interactive training course, an online educational platform, a 360º multi-stakeholder rotation and a research fellowship.
Why does data quality and traceability matter? Are you getting what you pay for? What resources are required for running a Fit For Filing trial?
Academic trials are not usually part of the marketing authorisation process of a new drug. But why is that? Let’s explore in this webinar series how we can open up this opportunity to enable academia-industry collaborative trials to deliver data that can be used for licensing purposes (fit for filing).
Academic trials are not usually part of the marketing authorisation process of a new drug. But why is that? Let’s explore how we can open up this opportunity to enable collaborative trials to deliver data that are fit for filing.
Early collaboration and communication between all stakeholders is crucial to develop better trial protocols and to collect adequate data and documentation.
Why does data quality and traceability matter? Are you getting what you pay for? What resources are required for running a Fit For Filing trial?
The educational webinar series “Everything you always wanted to know about Developing Drugs for Children with Cancer* (*But were afraid to ask)” aims to provide a comprehensive overview of drug development regulatory science for the community of paediatric oncology in both EU & USA.